---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-047670"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T02:59:52.444068+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Karyopharm FY2025 total rev $146M; XPOVIO $115M; net loss $196M; FY2026 guidance $130-150M; key trial readouts in 2026

## Summary
- FY2025 total revenue $146.1M (up from $145.2M); U.S. XPOVIO net product revenue $114.9M (up from $112.8M).
- FY2025 net loss $196.0M ($17.93/share) vs $76.4M prior year, driven by $62.4M loss on debt extinguishment.
- Cash, cash equivalents and investments $64.1M at Dec 31, 2025 vs $109.1M at Dec 31, 2024; runway into Q2 2026.
- FY2026 guidance: total revenue $130-150M, XPOVIO net product $115-130M, R&D+SG&A $230-245M.
- Phase 3 SENTRY myelofibrosis trial top-line data expected March 2026; Phase 3 endometrial cancer data mid-2026.

## SEC filing metadata
- accession: 0001193125-26-047670
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312526047670/0001193125-26-047670-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312526047670/kpti-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-047670
- JSON: https://secwatch.observer/filing/0001193125-26-047670.json
- Plain text: https://secwatch.observer/filing/0001193125-26-047670.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.